Thiazolidinediones Help Prevent Bone Loss in Arthritis
Author Information
Author(s): Koufany Meriem, Moulin David, Bianchi Arnaud, Muresan Mikhaela, Sebillaud Sylvie, Netter Patrick, Weryha Georges, Jouzeau Jean-Yves
Primary Institution: Laboratoire de Physiopathologie et Pharmacologie Articulaires (LPPA), UMR 7561 CNRS-Nancy Université
Hypothesis
Can thiazolidinediones reduce inflammation and bone loss in experimental polyarthritis?
Conclusion
Higher doses of thiazolidinediones are needed to treat arthritis effectively, but they can prevent inflammatory bone loss.
Supporting Evidence
- Thiazolidinediones reduced synovitis and inflammatory cytokine expression.
- Higher doses were required to achieve anti-inflammatory effects.
- Bone erosions were prevented despite increased fat mass.
- No significant improvement in cartilage lesions was observed.
Takeaway
This study shows that certain diabetes medications can help protect bones in arthritis, but they might also make you gain weight.
Methodology
Lewis rats were treated with different doses of rosiglitazone and pioglitazone for 21 days after inducing arthritis.
Potential Biases
Potential bias due to the use of a single animal model and the specific dosing regimen.
Limitations
The study did not assess long-term effects or the impact on cartilage changes.
Participant Demographics
Inbred male Lewis rats, weighing 150 to 175 g.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website